Cardiac Response to Change in the Mode and Frequency of Dialysis

Overview

About this study

The purpose of this study is to look at a population of stable End-stage renal disease (ESRD) patients receiving conventional hemodialysis (HD) or peritoneal dialysis, to evaluate the association of elevations in cTnT to: a) Levels of selected biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive C Reactive Protein (hsCRP), Asymmetric Dimethyl Arginine (ADMA); b) Clinical parameters – hypertension, hypotension on HD, left ventricular hypertrophy; c) Biochemical parameters – dyslipidemia, hyperphosphatemia, hyperparathyroidism, erythropoietin resistance.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ESRD patients who are switched to daily HD as part of clinical practice.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Allan Jaffe, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions